Advertisement

Molecular and Cellular Biochemistry

, Volume 462, Issue 1–2, pp 41–50 | Cite as

The effects of MAPK p38α on AZT resistance against reactivating HIV-1 replication in ACH2 cells

  • Xue WangEmail author
  • Jiangqin Zhao
  • Viswanath Ragupathy
  • Indira HewlettEmail author
Article

Abstract

Antiretroviral therapy (ART) has remarkably decreased HIV-related mortality. However, drug-resistant HIV variants pose a potential threat to the long-term success of ART. Both HIV mutants and host factors can cause HIV drug resistance. Using susceptible ACH2 cells chronically infected with HIV-1, we examined the effects of MAPK p38α on AZT resistance against reactivating HIV-1 replication that can be activated by HIV-1 superinfection. We found that HIV-1 superinfection induced more viral production, which was diminished by p38 inhibitor, SB203580, and by AZT in cells infected with non-AZT-resistant HIV-1 strain MN. p38α expression can resist action of AZT in inhibition of HIV-1 replication with increased expression of transcription factor, NF-ĸBp65, SP1, and c-Fos through activation of TCR-related pathways with upregulation of CD3, TCRα, TCRβ, Zap-70, PKC, PLCγ1, GRB2, and PI3K/Akt expression. In HIV-1 MN superinfection under AZT treatment, expression of p38α led to HIV vif expression and inhibited APOBEC3G expression. We also investigated effects of p38α on gp130/JAK-STAT pathways, in which p38α increased expression of protein, gp130, EGFR, Jak2, STAT1, STAT3, STAT5, ras, and TF. p38α could induce apoptotic pathways with upregulation of Fas, FADD, Caspase-8, p53, and Bax, and downregulation of Bcl2 expression. These results indicate that p38α plays a positive role in reactivation of viral replication from HIV-1 latent infection and leads to HIV-1 AZT resistance. In conclusion, MAPKp38α can activate HIV-1 replication inhibited by AZT from HIV-1 latent infection and may be used as a latency reversal agent. The activation involves induction of several cell signaling pathways that are required for HIV-1 replication, which may be integrated into future viral remission strategies.

Keywords

HIV MAPK p38α AZT Latency HIV-1 vif 

Notes

Acknowledgements

The authors wish to thank Dr. Krishnakumar Devadas and Dr. Mohan Setty for critical review of this manuscript. We further acknowledge the NIH AIDS reagent repository for the reagents. This work was supported by an internal CBER grant. The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.

Author contributions

XW and IH conceived and designed the experiments; XW, JZ, and VR performed the experiments; XW analyzed the data; and XW and IH wrote the paper. All authors have read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Clutter DS, Jordan MR, Bertagnolio S, Shafer RW (2016) HIV-1 drug resistance and resistance testing. Infect Genet Evol 46:292–307CrossRefGoogle Scholar
  2. 2.
    Shoko C, Chikobvu D (2018) Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa. Theor Biol Med Model 15:10CrossRefGoogle Scholar
  3. 3.
    Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR (2011) The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. Infect Disord Drug Targets 11:124–133CrossRefGoogle Scholar
  4. 4.
    Khandazhinskaya A, Matyugina E, Shirokova E (2010) Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects. Expert Opin Drug Metab Toxicol 6:701–714CrossRefGoogle Scholar
  5. 5.
    Raffe SF, Savage C, Perry LA, Patel A, Keith T, Howell R, Bradley R, Bomont R, Fidler K, Gilleece Y (2017) The management of HIV in pregnancy: a 10-year experience. Eur J Obstet Gynecol Reprod Biol 210:310–313CrossRefGoogle Scholar
  6. 6.
    Trushin SA, Algeciras-Schimnich A, Vlahakis SR, Bren GD, Warren S, Schnepple DJ, Badley AD (2007) Glycoprotein 120 binding to CXCR1 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4. J Immunol 178:4846–4853CrossRefGoogle Scholar
  7. 7.
    Eyers PA, Van Den Ijssel P, Quinlan RA, Goedert M, Cohen P (1999) Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett 451:191–196CrossRefGoogle Scholar
  8. 8.
    Clark JE, Sarafraz N, Marber MS (2007) Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharm Ther 116:192–206CrossRefGoogle Scholar
  9. 9.
    Kim JH, Mosca JD, Vahey MT, McLinden RJ, Burke DS, Redfield RR (1993) Consequences of human immunodeficiency virus type 1 superinfection of chronically infected cells. AIDS Res Hum Retrovir 9:875–882CrossRefGoogle Scholar
  10. 10.
    Kim JH, McLinden RJ, Mosca JD, Burke DS, Boswell RN, Birx DL, Redfield RR (1996) Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones. J Acquir Immune Defic Syndr Hum Retrovirol 12:329–342CrossRefGoogle Scholar
  11. 11.
    Wang X, Mbondji-Wonje C, Zhao J, Hewlett I (2016) IL-1β and IL-18 inhibition of HIV-1 replication in Jurkat cells and PBMCs. Biochem Biophys Res Commun 473:926–930CrossRefGoogle Scholar
  12. 12.
    Wang X, Sun B, Mbondji C, Biswas S, Zhao J, Hewlett I (2017) Differences in activation of HIV-1 replication by superinfection with HIV-1 and HIV-2 in U1 cells. J Cell Physiol 232:1746–1753CrossRefGoogle Scholar
  13. 13.
    Mbondji-Wonje C, Dong M, Wang X, Zhao J, Ragupathy V, Sanchez AM, Denny TN, Hewlett I (2018) Distinctive variation in the U3R region of the 5’ long terminal repeat from diverse HIV-1 strains. PLoS ONE 13:e0195661CrossRefGoogle Scholar
  14. 14.
    Heusinger E, Kirchhoff F (2017) primate lentiviruses modulate NF-κB activity by multiple mechanisms to fine-tune viral and cellular gene expression. Front Microbiol 8:198–209CrossRefGoogle Scholar
  15. 15.
    Le Sage V, Cinti A, Amorim R, Mouland AJ (2016) Adapting the stress response: viral subversion of the mTOR signaling pathway. Viruses 8:125–153CrossRefGoogle Scholar
  16. 16.
    Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA 105:5501–5506CrossRefGoogle Scholar
  17. 17.
    Okada A, Iwatani Y (2016) APOBEC3G-mediated G-to-A hypermutation of the HIV-1 genome: the missing link in antiviral molecular mechanisms. Front Microbiol 7:2027–2034CrossRefGoogle Scholar
  18. 18.
    Velu V, Shetty RD, Larsson M, Shankar EM (2015) Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 12:14–30CrossRefGoogle Scholar
  19. 19.
    Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T (1996) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808–1810CrossRefGoogle Scholar
  20. 20.
    Kishimoto T, Taga T, Akira S (1994) Cytokine signal transduction. Cell 76:253–262CrossRefGoogle Scholar
  21. 21.
    O’Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542–550CrossRefGoogle Scholar
  22. 22.
    Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP (2017) Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS Pathog 13:e1006740CrossRefGoogle Scholar
  23. 23.
    Wang X, Ragupathy V, Zhao J, Hewlett I (2011) Molecules from apoptotic pathways modulate HIV-1 replication in Jurkat cells. Biochem Biophys Res Commun 414:20–44CrossRefGoogle Scholar
  24. 24.
    Tan J, Wang X, Devadas K, Zhao J, Zhang P, Hewlett I (2013) Some mechanisms of FLIP expression in inhibition of HIV-1 replication in Jurkat cells, CD4 + T cells and PBMCs. J Cell Physiol 228:2305–2313CrossRefGoogle Scholar
  25. 25.
    Wang X, Tan J, Zhao J, Ragupathy V, Haleyurgirisetty M, Hewlett I (2014) Some findings of FADD knockdown in inhibition of HIV-1 replication in Jurkat cells and PBMCs. Mol Cell Biochem 393:181–190CrossRefGoogle Scholar
  26. 26.
    Swepson C, Ranjan A, Balasubramaniam M, Pandhare J, Dash C (2016) Cocaine enhances HIV-1 transcription in macrophages by inducing p38 MAPK phosphorylation. Front Microbiol 7:823–836CrossRefGoogle Scholar
  27. 27.
    Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J, Chen G (2003) p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 278:4831–4839CrossRefGoogle Scholar
  28. 28.
    Fong LE, Sulistijo ES, Miller-Jensen K (2017) Systems analysis of latent HIV reversal reveals altered stress kinase signaling and increased cell death in infected T cells. Sci Rep 7:16179–16191CrossRefGoogle Scholar
  29. 29.
    Anand AR, Prasad A, Bradley RR, Deol YS, Nagaraja T, Ren X, Terwilliger EF, Ganju RK (2009) HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. Blood 114:3588–3600CrossRefGoogle Scholar
  30. 30.
    Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734–739CrossRefGoogle Scholar
  31. 31.
    Lint CV, Bouchat S, Marcello A (2013) HIV-1 transcription and latency: an update. Retrovirology 10:67–104CrossRefGoogle Scholar
  32. 32.
    Ma L, Zhang Z, Liu Z, Pan Q, Wang J, Li X, Guo F, Liang C, Hu L, Zhou J, Cen S (2018) Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation. Sci Rep 8:8067CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Lab of Molecular Virology, Division of Emerging and Transfusion Transmitted DiseasesCenter for Biologics Evaluation and Research, Food and Drug AdministrationSilver SpringUSA
  2. 2.Lab of Molecular Virology, Division of Emerging and Transfusion Transmitted DiseasesCenter for Biologics Evaluation and Research, Food and Drug AdministrationSilver SpringUSA

Personalised recommendations